Oncology (all articles)
COVID-19 and cancer: Current challenges and perspectives
14 Oct, 2020 | 09:35h | UTCCOVID-19 and Cancer: Current Challenges and Perspectives – Cancer Cell
Trends in clinical profiles, organ support use and outcomes of patients with cancer requiring unplanned ICU admission: a multicenter cohort study
12 Oct, 2020 | 00:31h | UTC
Commentary on Twitter
Read @f_g_zampieri et al: #ICU: a place for complex #oncology patients? outcomes of critically ills w cancer improved in past 8y
> 30% bed/days use
reduced mortality/ICU LOS
-> improved overall care?
Open #FOAMcc on @yourICM at https://t.co/lUKQsZvLcR#CCCF2020 @Dr_Cit https://t.co/8R8lDKEZal pic.twitter.com/VJ5XZLoVrA— Intensive Care Medicine (@yourICM) October 7, 2020
Delivering cancer care during the covid-19 pandemic: recommendations and lessons learned from ASCO global webinars
2 Oct, 2020 | 09:19h | UTC
[Abstract Only] Atezolizumab for first-line treatment of PD-L1–selected patients with non–small-cell lung cancer
1 Oct, 2020 | 08:53h | UTCCommentary: Atezolizumab Leads to Longer OS for Some Types of Advanced NSCLC, Study Says – AJMC
[Abstract Only] Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer
1 Oct, 2020 | 08:56h | UTCHPV Vaccination and the Risk of Invasive Cervical Cancer – New England Journal of Medicine
News Release: HPV vaccine effective against cervical cancer – Karolinska Institutet
Randomized trials: Salvage radiotherapy vs. adjuvant radiotherapy after radical prostatectomy
29 Sep, 2020 | 10:03h | UTCRelated articles: Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial – The Lancet Oncology (free registration required) AND Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial – The Lancet Oncology (free registration required)
Commentaries: For Radiotherapy After Radical Prostatectomy, Salvage Therapy Should Be “Standard of Care” – NEJM Journal Watch AND Prostate cancer patients could be spared radiotherapy after surgery as new research suggests there is no benefit and it could be carried out later if the disease comes back – The Daily Mail
[Abstract Only] Meta-analysis: Adjuvant vs. early salvage radiotherapy for the treatment of localized and locally advanced prostate cancer
29 Sep, 2020 | 10:04h | UTCCommentaries: For Radiotherapy After Radical Prostatectomy, Salvage Therapy Should Be “Standard of Care” – NEJM Journal Watch AND Prostate cancer patients could be spared radiotherapy after surgery as new research suggests there is no benefit and it could be carried out later if the disease comes back – The Daily Mail
[Abstract Only] Meta-analysis: Direct oral anticoagulants for cancer-associated venous thromboembolism
28 Sep, 2020 | 01:22h | UTC
Advanced Prostate Cancer: AUA/ASTRO/SUO Guidelines
24 Sep, 2020 | 09:15h | UTCAdvanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I – The Journal of Urology
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II – The Journal of Urology
Clinical review: Emerging immunotherapies in multiple myeloma
23 Sep, 2020 | 14:33h | UTCEmerging immunotherapies in multiple myeloma – The BMJ
Commentary on Twitter
Despite advances in treatment in the past 20yrs, multiple myeloma remains an incurable disease. This review summarizes the evidence of these various immunotherapies, their mechanism of action, and data on treatments' safety and efficacy #BMJEducation https://t.co/JWeMlJ89YR
— The BMJ (@bmj_latest) September 22, 2020
[ESMO2020 press release – Not published yet] Randomized trial: No benefit for post-operative radiotherapy in non-small-cell lung cancer
22 Sep, 2020 | 09:23h | UTCCommentary: Phase 3 Trial Results Do Not Support PORT in Resected Stage IIIAN2 NSCLC – Targeted Oncology
Systematic review: Therapies for clinically localized prostate cancer
20 Sep, 2020 | 21:15h | UTCTherapies for Clinically Localized Prostate Cancer – Agency for Healthcare Research and Quality
Final report: Therapies for Clinically Localized Prostate Cancer AND Evidence Summary
[Abstract Only] Survival with Olaparib in metastatic castration-resistant prostate cancer
20 Sep, 2020 | 21:13h | UTC
Commentary on Twitter
The PROfound trial showed that olaparib prolonged imaging-based progression-free survival among patients whose tumors contained defects in the BRCA1, BRCA2, or ATM. With longer follow-up, the trial now shows that olaparib prolonged overall survival in these patients. #ESMO20
— NEJM (@NEJM) September 20, 2020
[Abstract Only] Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma
20 Sep, 2020 | 21:11h | UTC
Commentary on Twitter
Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy. #ESMO20
— NEJM (@NEJM) September 18, 2020
[Abstract Only] Randomized trial: Preoperative radiotherapy plus surgery vs. surgery alone for patients with primary retroperitoneal sarcoma
16 Sep, 2020 | 08:46h | UTCPreoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Consensus Statement: Cardio‐oncology care in the era of the COVID‐19 pandemic
14 Sep, 2020 | 00:54h | UTC
Commentary on Twitter
CA: A Cancer Journal Article on COVID and Cardio-Oncology Care from International Cardio-Oncology team of global experts! An outstanding achievement by our community- read it here: https://t.co/4GqnZfbWXN pic.twitter.com/9m9n744jSo
— International Cardio-Oncology Society (@ICOSociety) September 11, 2020
[Abstract Only] Randomized trial: Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide
10 Sep, 2020 | 09:33h | UTC
ESMO Expert Consensus: Managing cancer patients during the COVID-19 pandemic
6 Sep, 2020 | 21:40h | UTC
Cohort study: COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumor subtype and patient demographics
6 Sep, 2020 | 21:42h | UTCCommentaries: New study describes which cancer patients are more vulnerable to COVID-19 – University of Birmingham AND COVID-19 Prevalence and Mortality in Patients With Cancer in the UK – The ASCO Post
Malignant pleural effusions: New evidence on management
4 Sep, 2020 | 02:03h | UTCMalignant pleural effusions (MPE): new evidence on management – Evidently Cochrane
Original Review: Interventions for the management of malignant pleural effusions: a network meta‐analysis – Cochrane Library
[Abstract Only] CAR T-cell therapy for patients with relapsed or refractory large B-cell lymphomas
3 Sep, 2020 | 10:56h | UTCLisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study – The Lancet (link to abstract – $ for full-text)
[Abstract Only] Randomized trial: Second-look surgery plus hyperthermic intraperitoneal chemotherapy vs. surveillance in patients at high risk of developing colorectal peritoneal metastases
2 Sep, 2020 | 09:31h | UTC
Randomized trial: Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy for early breast cancer
21 Aug, 2020 | 02:27h | UTCCommentaries: Targeted intraoperative radiotherapy for early breast cancer—new evidence challenges traditional treatment – The BMJ Opinion AND Long-term TARGIT-A data support single-dose intraoperative breast cancer radiotherapy – medwire News
[Abstract Only] Randomized trial: Laparoscopic vs. open total gastrectomy for clinical stage I gastric cancer
21 Aug, 2020 | 02:18h | UTC
[Abstract Only] Randomized trial: Hypofractionated vs. conventional fractionated radiotherapy after breast-conserving surgery
18 Aug, 2020 | 07:15h | UTC